News & Media

Biotecnol forms a research collaboration with BioArtic Neuroscience AB and Uppsala University of Sweden on new diagnostic method for Alzheimer’s disease

20 February, 2015. Biotecnol Ltd of UK and BioArtic Neuroscience AB of Sweden, entered into a collaboration to develop a new in-vivo diagnostic tool for Alzheimer’s disease (AD) based on Biotecnol’s Tribody™ technolgy and BioArtic’s anti-amyloid beta (Aβ) antibodies. The research work will be conducted in the laboratories of Lars Lannfelt, Dept. of Public Health/Geriatrics at Uppsala University, Sweden.

Dr Neill Mackenzie , CBO Biotecnol commented, “We are very pleased that such a prestigious group has chosen our technology to solve the problem of delivering antibodies across the blood-brain barrier.We are looking forward to seeing some exciting results from the research”

Dr Pär Gellerfors, Founder of BioArctic, “We believe that this research will lead to a new in-vivo diagnostic tool for Alzheimer’s disease. The Tribody™ format that Biotecnol have developed offers potential solutions to the problem that we could not find in other technologies”

About the Tribody™ format

Tribody™ molecules are multi-specific antibodies, produced by established recombinant DNA technology methods, which utilize the natural in vivo heterodimerization of Fab fragments to form a scaffold, upon which additional functionality can be incorporated. As a result Tribodies are characterized by an unsurpassed versatility; they can incorporate up to three different binding sites and can combine different functions all in one single molecule.

About Biotecnol

Biotecnol is an immune-oncology company with a strong track-record in antibody drug development. The company has a proprietary antibody format -Tribody™- for engaging various immunological effector functions including T-cells, to destroy cancer cells. The Company is looking to strengthen this solid asset base of new agents in the immune-oncology field, by developing candidates with a dual approach involving novel targets. Biotecnol has fully integrated capabilities that allow the company to run and effectively manage its own drug development programmes, right from the antibody selection process to clinic proof of concept.

About BioArctic Neuroscience

BioArctic Neuroscience AB is a biopharmaceutical company carrying out research and development for new treatments of disorders in the nervous system. The company, which was founded in 2003, has a proprietary technology for therapeutic monoclonal antibodies, for the treatment of Alzheimer’s disease, Parkinson’s disease and other related neurological disorders. The most advanced project, BAN2401, is currently in late clinical development in early Alzheimer’s disease together with Eisai Co. Ltd. The company in-licensed 2008 a novel innovative treatment for spinal cord injuries, which now is progressing into clinical development. The company’s business model is to form strategic research alliances, joint ventures or license agreements with pharmaceutical industries and bring its drug candidates to the world market. The company, which is headquartered in Stockholm, has received early venture capital from Karolinska Development AB and Uppsala Holding AB.

Back to news